bioAffinity Technologies, Inc. (NASDAQ: BIAF) reported Q3 EPS of ($4.74), $4.65 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.45 million versus the consensus estimate of $1.55 million.

For earnings history and earnings-related data on bioAffinity Technologies, Inc. (BIAF) click here.